Japan's Taisho buys nearly 25% stake in Vietnam's DHG Pharma for $97M

Pill pack

Tokyo-based Taisho Pharmaceutical has bought a 24.5% stake in Vietnam's DHG Pharmaceutical, the country's top drug distributor that handles a wide range of prescription therapies, over-the-counter treatments and personal care products.

This comes as Vietnam opens up to foreign investment across a number of industries as part of policies such as signing the Trans-Pacific Partnership trade pact. The government holds a 43.3% stake in DHG, according to Thanh Nien News, while foreign investors including Taisho own 49%.

The stake of 21.3 million shares was valued at VND2.2 trillion ($97.2 million) by the newspaper. In a release, Taisho said the purchase is aimed at expanding its reach in the country and offering advice on aspects of the pharmaceutical business.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"Taisho Group believes that the transaction and Alliance will enable Taisho Group to share its knowledge, technology, and know-how in the pharmaceutical business with DHG, resulting in an increase in DHG’s sales and further growth of Taisho Group’s and DHG’s businesses in Asia," Taisho said in a release. "In addition, synergy is expected between DHG, with its strong presence in Vietnam, and Taisho Group."

Taisho in Japan is strong in OTC offerings and has had a Vietnam unit since 1999.

Vietnam's pharmacy shops operate in a largely cash economy, making distribution and payments an area ripe for new methods.

According to Taisho, DHG, based in Can Tho in southern Vietnam, reported a net profit of VND593 billion in the year ended Dec. 31, 2015.

- here's the release
- and a story from Thanh Nien News

Related Articles:
Pharma market bets on ASEAN in focus ahead of economic pact


Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.